ANDA 211304, held by Azurity Pharmaceuticals. Metaraminol Bitartrate.
As of Nov 21, 2026, ANDA 211304 (Metaraminol Bitartrate), held by Azurity Pharmaceuticals, was first approved by FDA on Aug 24, 2021, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 24, 2021 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Metaraminol BitartrateEQ 10MG BASE/ML · injectable;injection | Metaraminol Bitartrate | Rx |
| Oct 9, 2024 | Supplement 1Labeling · Standard review | Approved | None posted |
| Aug 24, 2021 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters